MicroRNA-27a contributes to the malignant behavior of gastric cancer cells by directly targeting PH domain and leucine-rich repeat protein phosphatase 2
© The Author(s). 2017
Received: 13 December 2016
Accepted: 16 March 2017
Published: 21 March 2017
Accumulating evidence indicates that microRNA-27a (miR-27a) is involved in carcinogenesis and tumor progression. However, the exact function and molecular mechanism of miR-27a in gastric cancer remain unclear.
Quantitative real-time PCR (qRT-PCR) was used to quantify the expression of miR-27a and its target gene. The function of miR-27a in gastric cancer was investigated through in vitro and in vivo assays (MTT assay, colony formation assay, flow cytometry assay, wound healing assay, migration and invasion assay, immunohistochemistry (IHC), immunofluorescence (IF) and Western blot). A luciferase reporter assay was conducted to confirm the target gene of miR-27a.
We found that miR-27a was commonly overexpressed in gastric cancer and high expression of miR-27a was associated with distant metastasis, lymph node metastasis, advanced T stage and advanced clinical stage. Functional assays demonstrated that overexpression of miR-27a in AGS cells accelerated cell proliferation, migration and invasion and suppressed apoptosis. Meanwhile, opposite results were observed in SGC-7901 cells when miR-27a was suppressed. Consistently, down-regulation of miR-27a inhibited the growth and metastasis of engrafted tumors in vivo. Furthermore, we found PH domain and leucine-rich repeat protein phosphatase 2 (PHLPP2) to be a new target of miR-27a, and downregulation of PHLPP2 could rescue the effect of anti-miR-27a in gastric cancer cells. In addition, miR-27a-mediated suppression of PHLPP2 led to stimulation of the AKT/GSK3β pathway.
Our data suggest that miR-27a functions as a crucial oncogenic miRNA in gastric cancer. It can promote proliferation and metastasis of tumor cells by suppressing PHLPP2 and activating the AKT/GSK3β pathway. Therefore, miR-27a is a potential novel therapeutic target in gastric cancer treatment.
KeywordsmiR-27a PHLPP2 Gastric cancer Proliferation Metastasis
Gastric cancer (GC) is a common tumor of the digestive system. In 2012, an estimated 951,600 new stomach cancer cases and 723,100 deaths occurred worldwide, and in less developed countries, liver and stomach cancers among men are the second and third most frequently diagnosed cancers, respectively . Although recent advancements in early detection, therapy, and prevention have partially enhanced the survival rate of early-stage GC, stage IV GC is still incurable and has a very poor 5-year survival rate of approximately 4–5% . The unlimited proliferation and strong metastasis capacities of GC tumor cells are the main causes of the high degree of malignancy and the poor overall survival. As we know, high recurrence and metastasis rates have always been the primary obstacle to improve the survival rate of GC. Over 70% of patients experience recurrent and metastatic disease following interventions . Therefore, it is of great significance to further elucidate the molecular mechanisms of GC and improve the current preventive and therapeutic strategies against this disease.
MicroRNAs (miRNAs) are a class of small non-coding, endogenous, single-stranded RNAs of 18–23 nucleotides in length, which regulate gene expression by promoting mRNA degradation or inhibiting translation by binding to the 3′-untranslated region(3′-UTR) of their target mRNAs in a sequence-specific manner [4–6]. It has been reported that more than 60% of protein translation is regulated by miRNAs. Convincing evidence has confirmed that miRNAs regulate a majority of cellular processes related to the biological behavior of tumors, including cell proliferation, apoptosis, differentiation and metastasis [7–9]. Dysregulation of miRNA expression has been found in various types of human cancers [10–14]. Compelling evidence has suggested that miRNAs are novel modulators of tumor progression and new targets for tumor therapy in GC [15, 16]. MicroRNA-27a (miR-27a) is located on chromosome 19 (19p13.1). The role of miR-27a in tumorigenesis differs in various cells and tissues. It is regarded as an oncogene in several types of tumors, such as osteosarcoma , laryngeal carcinoma  and breast cancer . However, miR-27a is suggested to be a cancer suppressive miRNA in esophageal squamous cell carcinoma  and colorectal cancer . Its functions and molecular mechanisms in GC need to be further investigated.
In the current research, we explored the hidden function of miR-27a in the carcinogenesis and development of GC. We identified that miR-27a was upregulated in GC cells and tissues and the increased expression of miR-27a led to the promotion of tumorigenicity and metastasis of GC. As we know, a miRNA exerts its function through its target genes. Here, we explored whether PH domain and leucine-rich repeat protein phosphatase 2 (PHLPP2) was a novel target of miR-27a. PHLPP2, an isoform of the PHLPP, has been reported to induce cell cycle arrest and apoptosis and to suppress tumor metastasis of various types of cancer [22–24]. PHLPP2can directly dephosphorylate and inactivate Akt at Ser473 and subsequently inhibit the PI3K/Akt signaling pathway [25, 26]. Our study suggested that miR-27a exerts its functions of promoting proliferation and metastasis in GC cells by activating the Akt signaling pathway via targeting PHLPP2.
Patients and tissue specimens
Clinical features of all patients included in this study
TCGA database (n = 40)
Collected tissue samples (n = 50)
N1 + N2
I + II
III + IV
Cell lines and culture
In this study, the human GC cell lines MGC-803, HGC-27, BGC-823, AGS and SGC-7901 and the normal gastric epithelial cell line GES-1 were obtained from the Cell Bank of Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). The cells were stored in liquid nitrogen and cultured in RPMI-1640 medium (Gibco, USA) supplemented with penicillin (100 IU/mL), streptomycin (100 mg/mL) and 10% FBS (fetal bovine serum) and maintained at 37 °C in a humidified incubator containing 5% CO2.
RNA isolation and quantitative real-time PCR (qRT-PCR)
Total RNA was isolated from tissue and cell specimens using Trizol (TaKaRa, China), and total RNA was extracted according to the manufacturer’s instructions. The RNA concentration was measured with a BioSpectrometer (Eppendorf, Germany). The RNA samples were reversely transcribed into cDNA using the TransScript RT reagent Kit (TransGen, China). QRT-PCR was performed with FastStart Universal SYBR Green Master (ROX) (Roche, USA). β-actin and U6 were used to normalize the level of mRNA and miRNA expression, respectively. β-actin primers were 5′-CTGGAACGGTGAAGGTGACA-3′ and 5′-AAGGGACTTCCTGTAACAATGCA-3′; PHLPP2 primers were 5′-CCAATGAGCAAGGACAGGAT-3′ and 5′-GGTCCTCTGGTTCCATCTGA-3′. The Bulge-Loop miRNA qRT-PCR Primer kit (RIBOBIO, China) was used for detecting miR-27a expression. QRT-PCR was performed using the CFX96 Real-Time system (Bio-Rad, USA), and the data were analyzed using the 2∆∆CT method.
Protein extraction and Western blot
Total cellular proteins were extracted using the cell lysis buffer for Western blot. The protein samples were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto PVDF membranes (Bio-Rad, USA). The membranes were blocked in 5% skim milk and then incubated with a specific primary antibody and a secondary antibody, and they were then detected by enhanced chemiluminescence (ECL). The immunoblots were visualized using the Image Quant LAS 4000 digital imaging system (GE, USA). The following primary antibodies were used: Antibodies for PHLPP2 (PA5-25995) and Vimentin (PA5-2723) were obtained from Thermo Fisher. Antibodies for GSK-3β (ab131356), p-GSK-3β (ab75814), P27 (ab62364), P21 (ab109520), CyclinD1 (ab134175), E-cadherin (ab152102) and Snail (ab82846) were purchased from Abcam. Antibodies for AKT (D260001) and p-AKT (D155022) were purchased from Sangon Biotech . While the β-actin antibody and the secondary antibodies were purchased from Beyotime.
Immunohistochemistry and immunofluorescence (IF) analysis
Paraffin blocks from GC and normal tissues were sectioned into 4-μM-thick sections. The samples were deparaffinized in xylene and rehydrated using a series of graded alcohol. The slides were blocked with 10% goat serum before incubation with the primary antibody. The samples were incubated overnight with a primary antibody and then with a secondary antibody. For immunofluorescence, cells were seeded in 96-well culture plates, incubated with primary antibodies and then incubated with fluorophore-conjugated secondary antibody. They were visualized using a microscope or an inverted fluorescence microscope TE-2000S (Nikon). 4′6-Diamidino-2-phenylindole (DAPI) and fluorophore-conjugated secondary antibodies were obtained from Beyotime (Shanghai, China).
MiR-27a agomirs (miR-27a) and antagomirs (anti-miR-27a) were used for gain-of-function and loss-of-function analyses. MiR-27a agomirs, miR-27a agomirs negative control (NC), miR-27a antagomirs, miR-27a antagomirs negative control, siRNA against PHLPP2 (siPHLPP2) and siRNA negative control were synthesized by Ribobio (Guangzhou, China). Oligonucleotides were transfected into GC cell lines using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s instructions.
Luciferase reporter assay
The wild-type 3′-UTR fragment of PHLPP2 was amplified by PCR and cloned into the XbaI and EcoRI sites of the dual-luciferase miRNA target expression vector (Promega, USA), the resulting vector was named wtPHLPP2-3′-UTR. The mutant variant of the PHLPP2 3′-UTR vector was generated from wtPHLPP2-3′-UTR by mutating nucleotides that potentially bind to miR-27a and named mtPHLPP2-3′-UTR. The vectors (wtPHLPP2-3′-UTR or mtPHLPP2-3′-UTR together with miR-27a agomirs or miR27a agomirs NC/miR-27a antagomirs or miR-27a antagomirs NC) were transfected into AGS and SGC-7901 cells using Lipofectamine 2000 reagent (Invitrogen). Luciferase activity was measured 48 h later with a dual-luciferase assay system (Promega) with a Synergy H1 Multi-Mode Microplate Reader (BioTek, USA). Luciferase activity ratios were presented as firefly luciferase values/renilla luciferase values.
Cell proliferation, colony formation, apoptosis and cell cycle assays
Tumor cell proliferation was assessed using the MTT and colony formation assays according to the manufacturer’s protocol. For the MTT assay, 0.5 × 104 cells per well were seeded in 96-well plates, and the OD490 was measured on days 1, 2, 3, 4 and 5. Five hundred gastric cancer cells per well were seeded in 6-well plates. After two weeks, colonies were fixed with methanol containing 0.2% crystal violet, and the number of colonies was counted. Furthermore, an apoptosis assay was performed 48 h after the transfection of miR-27a antagomirs, miR-27a agomirs or siPHLPP2 into SGC-7901 and AGS cells using the AnnexinV FITC/PI Apoptosis Detection Kit (Roche) and the Accuri C6 flow cytometer (BD, USA). In addition, cell cycle analyses were performed 48 h after the transfection of oligonucleotides into GC cells using a cell cycle detection kit (Keygen, Nanjing, China) and the Accuri C6 flow cytometer (BD, USA).
In vitro wound healing, tumor cell migration and invasion assays
For the wound healing assay, appropriate GC cells were seeded into 12-well plates, transfected with oligonucleotides and cultured for 1 day. After the cells achieved nearly 90% confluence, a line was scraped with a 10-μl pipette tip, cells were washed with medium until no floating cells were present. Then, the medium in the plates was replaced and the cells were cultured for 24 h. The speed of wound closure was imaged, and the rate of closure was calculated via counting changes of cell covered area for five randomly chosen fields. Tumor cell migration and invasion capacity were assessed using Transwell chambers (Corning, USA) in 24-well plates. In brief, tumor cells were transfected with the oligonucleotides, and 24 h later, they were resuspended in serum-free RPMI 1640 medium and seeded into the upper chamber of Transwells whose membrane was coated or not with or matrigel (BD, USA), while the lower chamber was filled with fresh medium containing 10% FBS. After 24 h of culture at 37 °C, the cells remaining in the top chambers were taken away carefully using cotton swabs, while the cells migrating and invading the lower surface of the chambers were fixed and stained with a solution containing 0.1% crystal violet (Beyotime, Shanghai, China) and 20% methanol, reviewed and photographed under a microscope at × 200 magnification in five random fields. The quantity of migrating and invading cells was assessed by counting together five different fields of view under an optical microscope.
Tumor xenograft model
Six- weeks old BALB/c nude mice (n = 12) were purchased from the Laboratory Animal Research Institute of the Beijing Chinese Academy of Medical Sciences and housed under specific pathogen-free conditions. All animal experiments were undertaken in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals, with the approval of the Scientific Investigation Board of the College of Basic Medicine, Jilin University. The nude mice received the subcutaneous injection of SGC-7901 cells into the flank. When the tumor volume reached 100 mm3, miR-27a antagomir or NC were inoculated into the xenograft tumor by multi-point injection once every 2 days, and these mice were closely observed for tumor growth. Tumor size was measured every 2 days with a digital caliper. The tumor volume was calculated using the formula: length × width2 × 0.5. Then, all mice were sacrificed, and tumors were removed, photographed and weighed. Tumor grafts from the nude mice were fixed with a formaldehyde solution and embedded in paraffin for IHC analysis. For the metastasis assay, the cells (2 × 106 cells per mouse) were vaccinated to the spleens of the mice. Two weeks later, miR-27a antagomir or NC were administered through the tail vein of each group respectively. Six weeks later nude mice were sacrificed. Then the livers of mice were removed and fixed with formaldehyde solution and embedded with paraffin. The paraffin fixed tissues were serially sectioned and stained by hematoxylin-eosin (HE) staining to identify metastatic nodules.
All statistical analyses were performed using SPSS 18.0 (SPSS Inc., Chicago, USA) and GraphPad Prism 6 (GraphPad Software Inc., CA, USA) software. Differences in the level of expression of miR-27a and PHLPP2 between GC and the corresponding normal tissues were evaluated using the paired t-test. The association of expression of miR-27a and PHLPP2 with clinical parameters was analyzed using the unpaired t-test. Correlation of miR-27a expression with that of PHLPP2 was conducted with the Pearson correlation test. For in vitro experiments, the t-test was used to analyze the difference between two groups. All P-values were two sided, and P < 0.05 was considered to be statistically significant. All data are presented as the mean ± standard deviation (SD) from at least three independent replicates.
MiR-27a is upregulated in gastric cancer tissues and cell lines
Biological effects of miR-27a on the regulation of cell viability, apoptosis and cell cycle distribution of gastric cancer cells
MiR-27a regulates migration and invasion in gastric cancer cells
MiR-27a directly targets PHLPP2 by binding to its 3′-UTR to inhibit PHLPP2 expression
PHLPP2 expression decreases in gastric cancer tissues and is inversely correlated with miR-27a levels
The result of PHLPP2 expression in gastric cancer tissues by qRT-PCR showed that PHLPP2 mRNA levels were reduced in GC tissues compared to adjacent normal tissues (Fig. 4e). lower expression of PHLPP2 was associated with advanced clinical stage (Additional file 1: Figure S2a), advanced T stage (Additional file 1: Figure S2b), advanced N stage (Additional file 1: Figure S2c) and advanced M stage (Additional file 1: Figure S2d). In addition, a remarkable relationship between miR-27a level and PHLPP2 level was observed in these tumor samples (r = −0.293, P = 0.039) (Fig. 4f). IHC analysis also showed that PHLPP2 expression was lower in GC tissues than in non-tumor tissues and that high malignant-degree tumor tissues have lower PHLPP2 expression (Fig. 4g).
MiR-27a exerts its function by suppressing PHLPP2 expression
MiR-27a activates the Akt/GSK3β pathway through PHLPP2 to exert its biologic effects on GC cells
Previous studies showed that PHLPP2 acts as a tumor suppressor gene by modulating a number of critical tumor progression regulators, and it has been reported that PHLPP2 functions through an Akt-independent pathway . Thus, we examined the expression of the components of the AKT pathway by Western blot. Western blot revealed that down-regulation of PHLPP2 abolished the anti-miR-27a mediated regulation of Akt phosphorylation and modulation of the cell cycle regulators p21, p27 and CyclinD1 (Figs. 2f, 5h). In addition, we observed that decreased expression of PHLPP2 could rescue cell migration and invasion impaired by miR-27a knockdown. Therefore, we hypothesized that mi-27a can also promote EMT by targeting PHLPP2 in GC. Western blot showed that silencing PHLPP2 abolished the effect of anti-miR-27a on p-GSK3β, E-cadherin, Vimentin and Snail (Figs. 3d, 5h). Immunofluorescence showed similar results on E-cadherin and Vimentin expression (Fig. 5i). Taken together, these findings confirm that miR-27a promotes GC cell proliferation and metastasis by regulating PHLPP2-mediated activation of the Akt/GSK3β pathway.
Down-regulation of miR-27a suppresses tumor growth and metastasis of GC in vivo
MiRNAs are a class of small RNAs that play an important role in regulating cellular activities in various living systems. They can profoundly affect the expression of a large number of genes that encode proteins. The precise function of individual miRNAs and their mRNA partners in normal and diseased tissues are being extensively investigated. MiRNAs have also been widely reported to act as essential regulators in tumors [4, 5, 16]. MiR-27a is one of the well-identified miRNAs in cancers, and its function is diverse, depending on the cancer types. In some tumors, it plays a role in promoting cancer, while in others it plays a role in tumor suppression [17–21]. Here, we confirmed that miR-27a was highly expressed in GC samples and cells. MiR-27a level was positively associated with the malignant degree of GC. Therefore, we explored the mechanism by which miR-27a influences the carcinogenesis of GC.
Functional in vitro studies suggested that overexpression of miR-27a significantly promoted growth, migration and invasion of GC cells. Furthermore, our xenograft mouse model also unveiled the suppressive effects of miR-27a knockdown on tumor growth and metastasis in vivo. Consistent with the data from the biological experiments, we found that the expression level of miR-27a was related to clinic-pathological characteristics, and the upregulated miR-27a expression was associated with distant metastasis, lymph node metastasis and advanced clinical stage. In review of the previous published literature, Zhou L et al. and Zhao X et al. also studied the role of miR-27a in GC. They reported that miR-27a promotes the proliferation of GC cells that is consistent with the result in our present study [30, 31]. In addition, we further studied the prometastatic effect of miR-27a in GC, and reported a new target gene of miR-27a.
In general, miRNAs perform their functions via suppression of specific target genes. To find a novel target through which miR-27a exerts its effects in GC, we employed an integrated approach using public bioinformatics tools. PHLPP2 was predicted as a direct target of miR-27a using bioinformatics algorithms. We next verified this prediction via qRT-PCR, Western blot and dual luciferase report assays. We found that the mRNA expression of PHLPP2 was significantly down-regulated in GC patient specimens and it was inversely associated with miR-27a levels. The levels of PHLPP2 mRNA and protein were reduced upon the upregulation of miR-27a in AGS cells, while the levels of PHLPP2 mRNA and protein were increased upon the down-regulation of miR-27a in SGC-7901 cells. As a member of the Ser/Thr protein phosphatase family, PHLPP2 is critical for suppressing cell survival by negatively modulating the signaling pathways stimulated by AKT, PKC, MAPK and Mst1 [32–36]. To confirm whether PHLPP2 is a target that mediates the function of miR-27a, we performed a loss of function approach to functionally characterize PHLPP2 in growth and metastasis of GC. We found that PHLPP2 silencing can partially attenuate the effects produced by miR-27a inhibition on cell proliferation, apoptosis, migration and invasion. Studies have shown that PHLPP2 can directly dephosphorylate AKT to inhibit its signaling activity [25, 26]. Our results revealed that p-AKT and CyclinD1 expression was down-regulated, p21 and p27 was upregulated in SGC-7901 cells where miR-27a was suppressed, while PHLPP2 silencing could abolish these changes. These findings indicate that the PHLPP2/AKT axis contributes to the miR-27a-mediated progression of GC. Meadow’s study found that AKT could promote EMT by suppressing the GSK3β kinase activity . Phosphorylated and inactivated GSK3β can promote the activity of Snail, further inhibiting E-cadherin expression and resulting in EMT [38, 39]. Cancer cell metastasis is highly related to EMT process. Aberrant expression of E-cadherin, Vimentin and Snail is associated with EMT and tumor metastasis [40, 41]. In this study, we found that the increase in the expression of miR-27a was associated with higher frequency of lymph node metastasis and distant metastasis in the patients with gastric cancer. By examining the expression of E-cadherin, Vimentin, Snail and p-GSK3β, we demonstrated that miR-27a might promote EMT through an Akt/GSK3β dependent pathway. Some previous studies also reported that miR-27a is related to cancer metastasis. Pan W et al. showed that miR-27a contributes to metastatic properties of osteosarcoma cells by targeting MAP2K4 . Li J et al. found that miR-27a promotes lung adenocarcinoma cells metastasis by interacting with RKIP . Here we found that miR-27a promoted gastric cancer cells metastasis by interacting PHLPP2, which is novel finding and has not been reported previously to the best of our knowledge.
In summary, our current study demonstrated that miR-27a possessed tumor inducing effects on gastric cancer through the novel target PHLPP2. Downregulation of miR-27a suppressed multiple malignant biological behaviors, including inhibition of tumor cell growth, and reduction of tumor cell migration and invasion. In addition, silencing of PHLLP2 could abolish malignant biological behaviors changes induced by inhibition of miR-27a. Conclusively, our findings indicated that miR-27a acted as an oncogene in GC and clarified its functional mechanism. Further studies will confirm if miR-27a could actually be used as a novel target for GC prevention and therapy.
We thank The Cancer Genome Atlas (TCGA) project for providing data. We also thank the American Journal Experts (AJE) for editing and proofreading this manuscript.
Support for the study was provided by the National Natural Science Foundation of China (No 31571443 to QY), the Jilin Provincial Science and Technology Department (Nos 20140414031GH and 20150101121JC to QY), and the Health and Family Planning Commission of Jilin Province (No 2014Z068 to QY).
Availability of data and materials
All data generated or analyzed during this study are included in this published article. Raw and processed data are stored in the laboratory of the corresponding authors and are available upon request.
QY designed the experiment and critically revised the paper; LD performed most of the experiments and wrote the manuscript; SYZ and PCS contributed to the patient recruitment and collected the data; XM performed the statistical and bioinformatic analysis; RWZ cultured cells and built animal models. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from all patients.
Ethics approval and consent to participate
This study was approved by the Ethics Committee of the School of Basic Medical Sciences, Jilin University and prior informed consent was obtained from all patients.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.View ArticlePubMedGoogle Scholar
- Thrumurthy SG, Chaudry MA, Chau I, Allum W. Does surgery have a role in managing incurable gastric cancer? Nat Rev Clin Oncol. 2015;12(11):676–82.View ArticlePubMedGoogle Scholar
- Gotoda T, Kusano C, Moriyasu F. Future perspective of gastric cancer endotherapy. Ann Transl Med. 2014;2(3):25.PubMedPubMed CentralGoogle Scholar
- Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.View ArticlePubMedPubMed CentralGoogle Scholar
- Lai EC. Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet. 2002;30(4):363–4.View ArticlePubMedGoogle Scholar
- Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 2011;3(3):83–92.PubMedPubMed CentralGoogle Scholar
- Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006;11(4):441–50.View ArticlePubMedGoogle Scholar
- He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–31.View ArticlePubMedGoogle Scholar
- Qu F, Li CB, Yuan BT, Qi W, Li HL, Shen XZ, Zhao G, Wang JT, Liu YJ. MicroRNA-26a induces osteosarcoma cell growth and metastasis via the Wnt/beta-catenin pathway. Oncol Lett. 2016;11(2):1592–6.PubMedGoogle Scholar
- Qian L, Zhang W, Lei B, He A, Ye L, Li X, Dong X. MicroRNA-101 regulates T-cell acute lymphoblastic leukemia progression and chemotherapeutic sensitivity by targeting Notch1. Oncol Rep. 2016;36(5):2511–6.PubMedPubMed CentralGoogle Scholar
- Zhai L, Ma C, Li W, Yang S, Liu Z. miR-143 suppresses epithelial-mesenchymal transition and inhibits tumor growth of breast cancer through down-regulation of ERK5. Mol Carcinog. 2016;55(12):1990–2000.View ArticlePubMedGoogle Scholar
- Dong P, Xiong Y, Watari H, Hanley SJ, Konno Y, Ihira K, Yamada T, Kudo M, Yue J, Sakuragi N. MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells. J Exp Clin Cancer Res. 2016;35(1):132.View ArticlePubMed CentralGoogle Scholar
- Wang FF, Wang S, Xue WH, Cheng JL. microRNA-590 suppresses the tumorigenesis and invasiveness of non-small cell lung cancer cells by targeting ADAM9. Mol Cell Biochem. 2016;423(1–2):29–37.View ArticlePubMedGoogle Scholar
- Cui S, Zhang K, Li C, Chen J, Pan Y, Feng B, Lu L, Zhu Z, Wang R, Chen L. Methylation-associated silencing of microRNA-129-3p promotes epithelial-mesenchymal transition, invasion and metastasis of hepatocelluar cancer by targeting Aurora-A. Oncotarget. 2016;7(47):78009–28.
- Cho WC. MicroRNAs in cancer - from research to therapy. Biochim Biophys Acta. 2010;1805(2):209–17.PubMedGoogle Scholar
- Yang Q, Zhang RW, Sui PC, He HT, Ding L. Dysregulation of non-coding RNAs in gastric cancer. World J Gastroenterol. 2015;21(39):10956–81.View ArticlePubMedPubMed CentralGoogle Scholar
- Tang J, Zhao H, Cai H, Wu H. Diagnostic and prognostic potentials of microRNA-27a in osteosarcoma. Biomed Pharmacother. 2015;71:222–6.View ArticlePubMedGoogle Scholar
- Tian Y, Fu S, Qiu GB, Xu ZM, Liu N, Zhang XW, Chen S, Wang Y, Sun KL, Fu WN. MicroRNA-27a promotes proliferation and suppresses apoptosis by targeting PLK2 in laryngeal carcinoma. BMC Cancer. 2014;14:678.View ArticlePubMedPubMed CentralGoogle Scholar
- Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007;67(22):11001–11.View ArticlePubMedGoogle Scholar
- Jiang Y, Duan Y, Zhou H. MicroRNA-27a directly targets KRAS to inhibit cell proliferation in esophageal squamous cell carcinoma. Oncol Lett. 2015;9(1):471–7.PubMedGoogle Scholar
- Bao Y, Chen Z, Guo Y, Feng Y, Li Z, Han W, Wang J, Zhao W, Jiao Y, Li K, et al. Tumor suppressor microRNA-27a in colorectal carcinogenesis and progression by targeting SGPP1 and Smad2. PLoS One. 2014;9(8):e105991.View ArticlePubMedPubMed CentralGoogle Scholar
- Nitsche C, Edderkaoui M, Moore RM, Eibl G, Kasahara N, Treger J, Grippo PJ, Mayerle J, Lerch MM, Gukovskaya AS. The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology. 2012;142(2):e371–5.View ArticleGoogle Scholar
- Liu J, Weiss HL, Rychahou P, Jackson LN, Evers BM, Gao T. Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene. 2009;28(7):994–1004.View ArticlePubMedGoogle Scholar
- O’Neill AK, Niederst MJ, Newton AC. Suppression of survival signalling pathways by the phosphatase PHLPP. FEBS J. 2013;280(2):572–83.View ArticlePubMedGoogle Scholar
- Brognard J, Niederst M, Reyes G, Warfel N, Newton AC. Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C. J Biol Chem. 2009;284(22):15215–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell. 2007;25(6):917–31.View ArticlePubMedGoogle Scholar
- Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005.
- Molina JR, Agarwal NK, Morales FC, Hayashi Y, Aldape KD, Cote G, Georgescu MM. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene. 2012;31(10):1264–74.View ArticlePubMedGoogle Scholar
- Li X, Stevens PD, Liu J, Yang H, Wang W, Wang C, Zeng Z, Schmidt MD, Yang M, Lee EY, et al. PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice. Gastroenterology. 2014;146(5):1301–12. e1301-1310.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhou L, Liang X, Zhang L, Yang L, Nagao N, Wu H, Liu C, Lin S, Cai G, Liu J. MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2. Oncotarget. 2016;7(32):51943–54.PubMedPubMed CentralGoogle Scholar
- Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res. 2011;30:55.View ArticlePubMedPubMed CentralGoogle Scholar
- Liao WT, Li TT, Wang ZG, Wang SY, He MR, Ye YP, Qi L, Cui YM, Wu P, Jiao HL, et al. microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2. Clin Cancer Res. 2013;19(17):4662–72.View ArticlePubMedGoogle Scholar
- Brognard J, Newton AC. PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab. 2008;19(6):223–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Richard S, Torabi N, Franco GV, Tremblay GA, Chen T, Vogel G, Morel M, Cleroux P, Forget-Richard A, Komarova S, et al. Ablation of the Sam68 RNA binding protein protects mice from age-related bone loss. PLoS Genet. 2005;1(6):e74.View ArticlePubMedPubMed CentralGoogle Scholar
- Shimizu K, Mackenzie SM, Storm DR. SCOP/PHLPP and its functional role in the brain. Mol BioSyst. 2010;6(1):38–43.View ArticlePubMedGoogle Scholar
- Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W, Stein J, Stein GS, Iglehart JD, Shi Q, et al. Mst1 is an interacting protein that mediates PHLPPs’ induced apoptosis. Mol Cell. 2010;38(4):512–23.View ArticlePubMedGoogle Scholar
- Meadows KN, Iyer S, Stevens MV, Wang D, Shechter S, Perruzzi C, Camenisch TD, Benjamin LE. Akt promotes endocardial-mesenchyme transition. J Angiogenes Res. 2009;1:2.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu J, Ru NY, Zhang Y, Li Y, Wei D, Ren Z, Huang XF, Chen ZN, Bian H. HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-beta signaling and is transcriptionally regulated by Slug. Oncogene. 2011;30(43):4410–27.View ArticlePubMedGoogle Scholar
- Kim JY, Kim YM, Yang CH, Cho SK, Lee JW, Cho M. Functional regulation of Slug/Snail2 is dependent on GSK-3beta-mediated phosphorylation. FEBS J. 2012;279(16):2929–39.View ArticlePubMedGoogle Scholar
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.View ArticlePubMedPubMed CentralGoogle Scholar
- Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Salah Z, Arafeh R, Maximov V, Galasso M, Khawaled S, Abou-Sharieha S, Volinia S, Jones KB, Croce CM, Aqeilan RI. miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells. Oncotarget. 2015;6(7):4920–35.View ArticlePubMedPubMed CentralGoogle Scholar
- Li J, Wang Y, Song Y, Fu Z, Yu W. miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Mol Cancer. 2014;13:193.View ArticlePubMedPubMed CentralGoogle Scholar